RT Journal Article
SR Electronic
T1 Using Survey Data to Estimate the Impact of the Omicron Variant on Vaccine Efficacy against COVID-19 Infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.21.22269636
DO 10.1101/2022.01.21.22269636
A1 Jesús Rufino
A1 Carlos Baquero
A1 Davide Frey
A1 Christin A. Glorioso
A1 Antonio Ortega
A1 Nina Reščič
A1 Julian Charles Roberts
A1 Rosa E. Lillo
A1 Raquel Menezes
A1 Jaya Prakash Champati
A1 Antonio Fernádez Anta
YR 2022
UL http://medrxiv.org/content/early/2022/01/21/2022.01.21.22269636.abstract
AB Data collected in the Global COVID-19 Trends and Impact Surveys (UMD Global CTIS), and data on variants sequencing from GISAID, are used to evaluate the impact of the Omicron variant (in South Africa and other countries) on the prevalence of COVID-19 among unvaccinated and vaccinated population, in general and discriminating by the number of doses. In South Africa, we observe that the prevalence of COVID-19 in December (with strong presence of Omicron) among the unvaccinated population is comparable to the prevalence during the previous wave (in August-September), in which Delta was the variant with the largest presence. However, among vaccinated, the prevalence of COVID-19 in December is much higher than in the previous wave. In fact, a significant reduction of the vaccine efficacy is observed from August-September to December. For instance, the efficacy drops from 0.81 to 0.30 for those vaccinated with 2 doses, and from 0.51 to 0.09 for those vaccinated with one dose. The study is then extended to other countries in which Omicron has been detected, comparing the situation in October (before Omicron) with that of December. While the reduction measured is smaller than in South Africa, we still found, for instance, an average drop in vaccine efficacy from 0.53 to 0.45 among those vaccinated with two doses. Moreover, we found a significant negative (Pearson) correlation of around −0.6 between the measured prevalence of Omicron and the vaccine efficacy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is partially supported by grant CoronaSurveys-CM, funded by IMDEA Networks and Comunidad de Madrid, Spain, and individual donations to the CoronaSurveys Project https://coronasurveys.org.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Board of IMDEA Networks Institute gave ethical approval for this work on 2021/07/05. IMDEA Networks has signed Data Use Agreements with Facebook, Carnegie Mellon University (CMU) and the University of Maryland (UMD) to access their data, specifically UMD project 1587016-3 entitled C-SPEC: SymptomSurvey: COVID-19 and CMU project STUDY202000000162 entitled ILI Community-Surveillance Study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data presented in this paper and some of the programs used to process it are openly accessible at https://github.com/GCGImdea/coronasurveys/tree/master/papers/omicron_efficacy_paper_medRxiv. https://github.com/GCGImdea/coronasurveys/tree/master/papers/omicron_efficacy_paper_medRxiv https://raw.githubusercontent.com/GCGImdea/coronasurveys/master/data/estimates-confirmed/PlotData/ https://raw.githubusercontent.com/GCGImdea/coronasurveys/master/data/common-data/unified-country-list.csv https://raw.githubusercontent.com/owid/covid-19-data/master/public/data/owid-covid-data.csv https://raw.githubusercontent.com/owid/covid-19-data/master/public/data/variants/covid-variants.csv